Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

priority access

- PMLiVE

Johnson & Johnson to expand dermatology portfolio with $850m Proteologix acquisition

The company will gain access to two treatments for atopic dermatitis

- PMLiVE

AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

- PMLiVE

AstraZeneca/Sanofi reveal promising real-world data for Beyfortus in infant RSV

The treatment reduced RSV hospitalisations by 82% in infants under six months during the 2023 to 2024 RSV season

- PMLiVE

AstraZeneca begins global withdrawal of COVID-19 vaccine following decline in demand

The company applied to voluntarily withdraw its European marketing authorisation on 5 March

- PMLiVE

AstraZeneca’s Calquence combination shows promise in untreated mantle cell lymphoma

The rare form of non-Hodgkin lymphoma is estimated to affect more than 27,500 people globally

- PMLiVE

Johnson & Johnson shares positive results for TAR-200 in high-risk bladder cancer

More than 83,000 cases of bladder cancer are diagnosed in the US every year

- PMLiVE

NHS primary care panel – the GP Contract and Operational Planning Guidance – Live Webinar

What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future...

Mtech Access

- PMLiVE

Novartis and PeptiDream expand peptide discovery collaboration in deal worth over $2.8bn

The agreement builds on the companies’ peptide-drug conjugate collaboration announced in 2019

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu shows promise in phase 3 breast cancer study

More than two million cases of breast cancer were diagnosed globally in 2022

- PMLiVE

Merck’s adult-specific pneumococcal vaccine shows promise in late-stage study

There are more than 100 types of pneumococcal bacteria, which can affect adults differently than children

- PMLiVE

AstraZeneca’s Truqap plus Faslodex receives CHMP recommendation for advanced breast cancer

More than 550,000 new cases of breast cancer were diagnosed in Europe in 2022

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links